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Viral and bacterial infections are involved in the development of human cancers, such as liver, nasopharyngeal,
cervical, head and neck, and gastric cancers. Aberrant DNA methylation is frequently present in these cancers, and
some of the aberrantly methylated genes are causally involved in cancer development and progression. Notably,
aberrant DNA methylation can be present even in non-cancerous or precancerous tissues, and its levels correlate
with the risk of cancer development, producing a so-called ‘epigenetic field for cancerization’. Mechanistically, most
viral or bacterial infections induce DNA methylation indirectly via chronic inflammation, but recent studies have
indicated that some viruses have direct effects on the epigenetic machinery of host cells. From a translational
viewpoint, a recent multicenter prospective cohort study demonstrated that assessment of the extent of alterations
in DNA methylation in non-cancerous tissues can be used to predict cancer risk. Furthermore, suppression of
aberrant DNA methylation was shown to be a useful strategy for cancer prevention in an animal model. Here, we
review the involvement of aberrant DNA methylation in various types of infection-associated cancers, along with
individual induction mechanisms, and we discuss the application of these findings for cancer prevention, diagnosis,
and therapy.Background
Viral and bacterial infections are strongly related to hu-
man carcinogenesis, and viral infections account for 10–
15 % of human cancers worldwide [1, 2]. Infection-
associated cancers (Table 1) include hepatocellular car-
cinomas (HCCs) induced by the hepatitis B virus (HBV)
and hepatitis C virus (HCV) [3–5]; lymphomas, naso-
pharyngeal cancers (NPCs), and gastric cancers associ-
ated with the Epstein-Barr virus (EBV) [6, 7]; cervical
and head and neck squamous cell cancers (HNSCCs) in-
duced by human papillomavirus (HPV) [8, 9]; Merkel
cell carcinoma associated with Merkel cell polyomavirus
(MCPyV) [10, 11]; and gastric cancers induced by Heli-
cobacter pylori [12]. The carcinogenic mechanisms of
these infection-associated cancers have been extensively
investigated, focusing on the effects of viral and bacterial
infections and the resultant inflammation on cell prolif-
eration, cell signaling, and genetic alterations [1].* Correspondence: tushijim@ncc.go.jp
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terations is now regarded as one of the most important
mechanisms mediating the effect of viral or bacterial in-
fections on cancer development. The first reports of an
association between viral infections and DNA methyla-
tion date back to the 1970s; these reports demonstrated
an increase in global 5-methylcytosine in cells trans-
formed by adenovirus and polyomavirus [13, 14]. In the
2000s, aberrant DNA methylation of tumor-suppressor
genes was detected first in EBV-infection-associated can-
cers [15] and then in gastric mucosae of individuals with
H. pylori infection [16, 17]. To date, many studies have
demonstrated a relationship between viral or bacterial
infections and aberrant DNA methylation [18–20].
Chronologically, aberrant DNA methylation can
already have accumulated in non-cancerous or precan-
cerous tissues, producing an ‘epigenetic field defect’ or
‘epigenetic field for cancerization’ [21]. The epigenetic
field for cancerization is characterized by accumulation
of aberrant methylation of various genes in a tissue with-
out clonal lesions, and by the correlation between theis article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Infection-associated cancers and aberrant DNA methylation
Bacterium or
virus
Cancer type Tumor-suppressor genes methylated Direct or
indirect effect
Factors involved in induction
of aberrant methylation
Helicobacter pylori Gastric cancer p16, LOX [39], miR-124a [47], miR-34b/c [48],
ANGPTL4 [46], FHL1 [44]
Indirect Inflammation
Epstein-Barr virus Gastric cancer p73 [72], TFF1 [73] Direct and/or
indirect
Latent membrane proteins
Nasopharyngeal cancer DLC1 [79], DAPK [77], p15, p16, RASSF1A,
TSLC1 [78]
Unknown Unknown
Burkitt’s lymphoma BIM, PRDM1 [84] Unknown Unknown





Hepatitis C virus Hepatocellular carcinoma p16 [97], RASSF1A, GSTP1 [98], RIZ1 [103] Indirect Inflammation
Human
papillomavirus
Head and neck squamous
cell carcinoma
p16, CDH1, RARβ [115], MGMT [114],
DAPK [113], DCC, GALR1, GALR2
Unknown Unknown





Merkel cell carcinoma RASSF1A [161] Unknown Unknown
HBx HBV encoded protein X
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vance of this concept has recently been demonstrated by
a multicenter prospective cohort study to predict risk of
metachronous gastric cancer [22].
Mechanistically, aberrant DNA methylation can be in-
duced directly by a component(s) of an infectious agent,
as recently shown for EBV [19, 23, 24]. Alternatively and
more commonly, aberrant DNA methylation can be in-
duced by chronic inflammation, as robustly shown for
H. pylori and hepatitis viruses [25, 26]. In addition, a re-
cent study suggested that chronic inflammation could
induce histone modification changes more frequently
and much earlier than aberrant DNA methylation, and
that some of the aberrant histone modifications can
serve as a signal for aberrant DNA methylation [27].
In this review, we first summarize the effect of H. pyl-
ori infection, whose role in induction of aberrant DNA
methylation and gastric carcinogenesis has been inten-
sively studied, and introduce the mechanisms of how H.
pylori infection induces aberrant DNA methylation.
Then, we introduce several viral infections that induce
aberrant epigenetic alterations, especially DNA methyla-
tion, and discuss the mechanisms involved. Finally, we
discuss the applications of infection-induced epigenetic
alterations for cancer prevention, diagnosis, and therapy.
Helicobacter pylori in gastric cancers
The vast majority of gastric cancer cases worldwide are
induced by H. pylori infection. It is an archetypal cancer
in which chronic inflammation and epigenetic alter-
ations are interconnected. The mechanisms by which H.
pylori infection induces aberrant DNA methylation have
been investigated in gastric cancers, cell lines, andanimal models [25, 28]. The epigenetic nature of gastric
cancer was recently reported [29].
Association among H. pylori infection, epigenetic
alterations, and gastric cancer
Gastric cancer is one of the most common malignancies
worldwide, especially in Asia and some European coun-
tries [30]. The major risk factor is persistent H. pylori in-
fection [31]; risk is elevated 2.2- to 21-fold by H. pylori
infection [12, 32, 33]. In some Asian countries, nearly all
gastric cancer patients have a history of H. pylori infec-
tion [2]. H. pylori is a Gram-negative bacterium [34, 35]
and is thought to be transmitted orally within families
during early childhood owing to poor hygiene. Few bac-
teria can survive in the stomach because of its low pH
maintained by the production of gastric acids; however,
H. pylori can survive for decades because of its produc-
tion of urease, which neutralizes its immediate environ-
ment [36]. It induces chronic gastritis characterized by
persistent infiltration of neutrophils and mononuclear
cells, and gastric atrophy [37]. Gastric atrophy is also a
strong risk factor for gastric cancer (hazard ratio = 14.09
(95 % confidence interval (CI) = 7.03–28.26)) [38].
Deep involvement of aberrant DNA methylation in
human gastric cancers had been suggested by the fact
that tumor-suppressor genes, such as CDH1, p16, and
hMLH1, were inactivated more frequently by aberrant
DNA methylation of their promoter CpG islands than
by genetic alterations [39]. More recently, integrated
analysis of DNA methylation and genetic alterations in
gastric cancer has revealed that genes involved in
cancer-related pathways were more frequently affected
by DNA methylation than by genetic alterations [29, 40].
Hattori and Ushijima Genome Medicine  (2016) 8:10 Page 3 of 13Furthermore, recent exome and whole-genome analyses
of gastric cancers have revealed new mutated driver
genes, such as ARID1A, FAT4, and RHOA, but the inci-
dences of mutations were 14 %, at the most, among the
cancers analyzed [41, 42]. Importantly, a significant
number of cancers have few mutations; according to a
report by Wang et al. [41], 5 of 100 cancers had no mu-
tations, and 22 cancers had only one mutation. These re-
ports support the major role of DNA methylation in
gastric cancer.
The link between H. pylori infection and DNA methy-
lation in gastric mucosae was first discussed in two
contradictory reports in 2003. Chan et al. [43] demon-
strated that promoter methylation of the tumor-
suppressor gene CDH1 was more frequent in the gastric
mucosae of individuals with H. pylori infection than in
uninfected individuals. In contrast, Kang et al. [16] did
not detect a difference in the number of methylated
genes between the gastric mucosae of individuals with
and without H. pylori infection. A quantitative DNA
methylation analysis of passenger genes (defined as those
that do not have a causal role in carcinogenesis) [17]
later convincingly demonstrated that H. pylori infection
was associated with increased DNA methylation levels in
gastric mucosae. These findings highlight the import-
ance of accurate quantification of DNA methylation and
analysis of appropriate genes.
The increased DNA methylation levels in non-
cancerous gastric mucosae with H. pylori infection were
observed in various but specific genes, including a small
number of tumor-suppressor genes, such as p16,
ANGPTL4, and FHL1, and a large number of passenger
genes [44–46]. In addition to protein-coding genes,
microRNA genes, including miR-124a and miR-34b/c,
were also aberrantly methylated in non-cancerous gastric
mucosae infected with H. pylori [47, 48]. Importantly, the
levels of DNA methylation of various methylated genes
were relatively consistent and correlated with the risk of
gastric cancer development [17, 49].
To investigate the cell types with aberrant methylation
of these genes, normal gastric epithelial cells were puri-
fied from an animal model, and the presence of aberrant
DNA methylation in these gastric epithelial cells was
shown [25]. Three positions within the stomach (an-
trum, middle body, and upper body) had increased
methylation levels in individuals with high risk of gastric
cancers compared with corresponding positions in the
stomach in individuals with low risk [49].
Therefore, aberrant DNA methylation of various spe-
cific genes is accumulated in normal gastric epithelial
cells in various positions within the stomach of individ-
uals with high risk of gastric cancers, and an ‘epigenetic
field defect’ or an ‘epigenetic field for cancerization’,
which is an area or even an entire tissue predisposed tocancer development, is produced [21]. Generally, the
presence of a cancerization field has been known for de-
cades, but it has been explained by mutation accumula-
tion [50]. Now, based on the findings in gastric cancer
[21], accumulation of epigenetic alterations in non-
cancerous or precancerous tissue has been shown to be
important. The concept is likely to be expanded to sev-
eral types of other infection-associated cancers, and has
great value as a risk marker, as discussed later.
Mechanisms of induction of aberrant DNA methylation by
H. pylori infection
From the viewpoint of H. pylori infection-induced
gastric carcinogenesis, most research has traditionally fo-
cused on cell proliferation, induction of genetic instabil-
ity and mutations, and activation of cellular signaling
[51–54]. For example, in the Mongolian gerbil animal
model (Meriones unguiculatus), in which H. pylori infec-
tion markedly promotes gastric carcinogenesis by a
mutagen such as N-methyl-N-nitrosourea [55], chronic
inflammation due to H. pylori infection was shown to
induce increased cell proliferation, and this may cause
further accumulation of mutations [56]. However, induc-
tion of aberrant DNA methylation can be even more im-
portant as described above.
Aberrant DNA methylation can potentially be induced
by two mechanisms: directly by a component of H. pyl-
ori, such as DNA methyltransferase, being injected into
gastric epithelial cells through a bacterial type IV secre-
tion system [57]; or indirectly due to inflammation
triggered by H. pylori infection. To clarify which mech-
anism is important, Niwa et al. [25] used Mongolian ger-
bils, in which aberrant DNA methylation was induced
by H. pylori infection in a manner similar to that ob-
served in humans. They treated gerbils infected with H.
pylori with an immunosuppressant, cyclosporine A, and
found that the induction of aberrant DNA methylation
was strongly suppressed, whereas H. pylori colonization
itself was not affected or was even augmented [25]. In
addition, one week after H. pylori eradication, when no
H. pylori remained in the stomach but inflammation still
persisted, aberrant DNA methylation continued to be in-
duced. These data showed that inflammation triggered
by H. pylori infection, but not by H. pylori itself, is in-
volved in induction of aberrant DNA methylation
(Fig. 1).
The next questions are what types of inflammation are
involved in DNA methylation induction and what cyto-
kines or molecules mediate the signal from the inflam-
mation. In gerbils, repeated administration of high
concentrations of ethanol or salt (NaCl) induced persist-
ent severe inflammation accompanied by strong induc-
tion of cell proliferation, but did not result in induction
of aberrant DNA methylation [28]. H. pylori infection



















Fig. 1 Mechanisms of induction of aberrant DNA methylation by H.
pylori infection. Acute inflammation following infection by H. pylori
develops into chronic inflammation characterized by the transition
of neutrophil infiltration to that of lymphocytes and macrophages.
Chronic inflammation signals, including cytokines such as IL-1β and
TNF-α and/or nitric oxide production, are associated with the induction
of aberrant DNA methylation. Aberrant DNA methylation is induced
both in driver genes (schematically represented by genes 1 and 2) that
are causally involved in gastric cancer development and in passenger
genes (genes 3 and 4) that are methylated in association with gastric
carcinogenesis in normal-appearing tissues. Driver genes are
methylated only at very low levels (shown in blue), showing that
such events are present only in a very small fraction of cells,
whereas many passenger genes are methylated at high levels
(shown in black), showing that their methylation is present in a
large fraction of cells. The accumulation of aberrant DNA methylation in
normal-appearing tissues produces an ‘epigenetic field for cancerization’,
which is an area of tissue or an entire tissue without clonal growth but
predisposed to cancer development
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tion of inflammatory cell types from polymorphonuclear
cells (mainly neutrophils) to mononuclear cells (lympho-
cytes and macrophages), with some remnant neutrophils
[58]. In contrast, prolonged treatment with ethanol or
salt induced repeated acute inflammation, characterized
by persistent neutrophil infiltration [28]. This indicates
that a specific type of inflammation, possibly character-
ized by mononuclear cell infiltration, is required for in-
duction of aberrant DNA methylation.
Regarding the responsible cytokines or molecules, in-
creased expression of Cxcl2, Il1b, and Tnf (which encodecytokines) and Nos2 (which encodes nitric oxide (NO)
synthase) were present in gastric mucosae of gerbils with
H. pylori infection, but not in those of gerbils exposed to
ethanol- or salt-induced inflammation [42]. The potential
involvement of IL1B in human gastric cancer is further ev-
idenced by the association between polymorphisms in the
IL1B promoter and gastric cancer susceptibility, especially
among individuals with H. pylori infection [59, 60], al-
though Il1b-deficient mice were resistant to H. pylori-in-
duced gastric cancers [61]. IL1B promoter polymorphisms
were also associated with the presence of the CpG island
methylator phenotype, a distinct phenotype with frequent
aberrant DNA methylation of multiple CpG islands, in
gastric cancers [62]. Also, treatment of gastric cancer
cell lines (TMK-1, MKN-74, and MKN-7) with IL-1β
has been reported to have induced the methylation of
tumor-suppressor gene CDH1, based on a conventional
methylation-specific PCR [62, 63].
NO, whose production is enhanced by an H. pylori ex-
tract [64] and IL-1β [65], was reported to upregulate the
enzyme activity of DNA methyltransferases (DNMTs)
without affecting mRNA expression levels [65]. However,
the enhancement of DNMT activity by NO has not been
confirmed since then. In addition, no changes in the
mRNA level of genes encoding DNMTs have been ob-
served in human or gerbil stomachs infected with H. pyl-
ori [25, 66] and in mouse colonic epithelial cells exposed
to chronic inflammation [67]. Therefore, the molecules
involved in the addition or maintenance of a methyl
group are unlikely to be affected, and we suggest that
factors that protect DNA from methylation, such as
TET proteins, are likely to be affected by chronic inflam-
mation, possibly via signals from macrophages, such as
IL-1β, TNF-α, or NO (Fig. 1).
EBV and cancer
EBV was the first virus detected in human neoplastic
cells (in a Burkitt’s lymphoma cell line), in 1964 [68],
and is involved in several tumor types. It was recently
shown to have a direct effect on induction of aberrant
DNA methylation based on an infection system of re-
combinant EBV in vitro [19, 23, 24].
Association among EBV infection, epigenetic alterations,
and cancer
EBV infection is epidemiologically associated with devel-
opment of human tumors, such as Burkitt’s lymphoma,
Hodgkin’s lymphoma, peripheral natural killer/T-cell
lymphoma, smooth muscle tumor, NPCs, and gastric
cancer [7]. EBV, a gamma-herpes virus consisting of
double-stranded DNA, maintains itself as an episomal
circular DNA in the nuclei of infected cells without the
production of viral particles, and it is not integrated into

























Fig. 2 Molecular mechanisms of induction of aberrant DNA
methylation by Epstein-Barr virus (EBV) infection. In gastric epithelial
cells, EBV is transferred to normal epithelial cells from EBV-infected B
lymphocytes. EBV produces multiple viral proteins, including latent
membrane protein 2A (LMP2A), which activates STAT3. STAT3 induces
increased expression of DNMT1, leading to upregulation at the mRNA
and protein levels. Upregulation of DNMT1 by STAT3 induces aberrant
DNA methylation of multiple genes, including both driver (shown
in blue) and passenger (shown in black) genes
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cence and become lifelong virus carriers, malignant neo-
plasms develop in a limited number of carriers.
Approximately 10 % of all gastric cancer cases are
EBV-associated, and monoclonal growth of EBV-infected
gastric epithelial cells is detected in gastric mucosae
[71]. Aberrant DNA methylation was observed more fre-
quently in EBV+ cancers than in EBV- cancers [15], and
hypermethylation of several specific genes, such as p73
and TFF1, has also been reported [72, 73]. Genome-wide
effects of EBV on DNA methylation were revealed by
Matsusaka et al. [74], and gastric cancers were categorized
into three distinct groups, EBV- and low methylation,
EBV- and high methylation, and EBV+ and extensively
high methylation.
In nasopharyngeal cancer, 70–90 % of the differenti-
ated type is associated with EBV infection [75], and pre-
malignant lesions of the nasopharyngeal epithelium are
EBV+, suggesting the occurrence of EBV infection at an
early step in carcinogenesis [76]. In primary cancers, ab-
errant DNA methylation has been observed at tumor-
suppressor genes, including DAPK1, DLC1, p15, p16,
and RASSF1A [77–79]. Significant association has been
observed between the levels of promoter methylation of
RASSF1A and TSLC1 tumor-suppressor genes and the
quantity of EBV DNA detected in cancer tissues and in
adjacent and distant non-cancerous tissues [78].
In lymphoma, EBV is present in over 95 %, 5–10 %,
and 3–40 % of endemic, sporadic, and HIV-associated
Burkitt’s lymphoma cases, respectively [80], in approxi-
mately 40 % of Hodgkin’s lymphoma cases [81], and in
2–9 % of diffuse large B-cell lymphoma cases [82].
Aberrant DNA methylation of tumor-suppressor genes,
including BIM and PRDM1, was detected in EBV+ Bur-
kitt’s lymphoma cases but not in EBV- cases [83, 84].
Hansen et al. [85] identified large-scale hypomethylated
blocks, which encompassed several Gb or were at least
longer than 1 Mb, in EBV-transformed B cells by a
genome-wide analysis, suggesting that at the early stage
of EBV-associated carcinogenesis, global hypomethyla-
tion occurs first, leading to genome instability and even-
tually to the induction of aberrant DNA methylation.
Mechanisms of induction of aberrant DNA methylation by
EBV
The causal role of EBV infection in inducing high levels
of DNA methylation was confirmed by forcing EBV ex-
pression in a gastric cancer cell line and observing ac-
quisition of new DNA methylation within 18 weeks [19].
Introduction of latent membrane protein 1 (LMP1), a
viral oncoprotein from EBV, into a breast cancer cell line
(MCF-7) activated DNMT1, DNMT3A, and DNMT3B,
and induced methylation-silencing of tumor-suppressor
gene CDH1 [86]. LMP1 directly activated the DNMT1promoter via the JNK-AP1 pathway [87]. Latent mem-
brane protein 2A (LMP2A) also induced DNMT1 over-
expression via STAT3 activation [88], which led to
methylation-silencing of tumor-suppressor gene PTEN.
In contrast with epithelial cells, EBV infection of germi-
nal center B cells, the presumptive progenitors of Hodg-
kin’s lymphoma, down-regulated DNMT1 and DNMT3B
via LMP1, whereas DNMT3A was upregulated at the
mRNA and protein levels [89]. Taken together, EBV in-
fection is considered to induce aberrant DNA methyla-
tion by its direct effect, namely via dysregulation of
DNMTs (Fig. 2).
HBV and HCV and hepatocellular carcinoma
Infections by HBV and HCV induce chronic hepatitis,
and are the major cause of HCC. Involvement of aber-

























Fig. 3 Molecular mechanisms of induction of aberrant DNA
methylation by hepatitis B virus (HBV). Two mechanisms of HBV-induced
DNA methylation have been proposed: a direct effect via hepatitis B
virus protein X (HBx) and an indirect effect via chronic inflammation. In
the direct mechanism, after HBV infection of hepatocytes, viral DNA is
transferred into the nucleus and transcribed. HBx is translated using
the host machinery, transported back to the nucleus, and involved in
upregulation of DNMT genes and recruitment of DNMTs to target
genes. In the indirect mechanism, chronic inflammation triggered by
HBV infection induces NK cell accumulation, increased Ifng expression,
and reactive oxygen species (ROS) production. Although the molecular
details remain to be elucidated, an NK-cell-dependent innate immune
response is important for methylation induction
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progression (from chronic hepatitis to liver cirrhosis and
to HCC). A recent report also showed the importance of
the immune response in the induction of methylation by
HBV or HCV [26].
HBV is a DNA virus and can be integrated into the
host genome, leading to virus-related insertional muta-
genesis of tumor-related genes [90]. However, it used to
be considered that there was no consensus pattern of in-
sertional mutations among HBV-induced HCC samples
[3, 91, 92]. Recent whole-genome sequencing analysis of
HCCs revealed that, although HBV was frequently inte-
grated into the TERT locus, most other frequently mu-
tated genes had incidences of less than 10 % [93, 94].
HCV is an RNA virus and cannot be integrated into the
host genome, but HCV core protein interacts with mul-
tiple proteins of host cells and these interactions induce
host responses [95, 96].
Association among hepatitis virus infection, aberrant DNA
methylation, and hepatocellular carcinoma
Epigenetically, similar to cancers of other tissues, HCCs
are characterized by hypomethylation of repetitive se-
quences, associated with genomic instability, and aber-
rant DNA methylation of tumor-suppressor genes, such
as RASSF1A, p16, SFRP1, GADD45A, and p15 [18, 97,
98]. These epigenetic alterations accumulate during the
course of HCC development [99]. For example, decreased
methylation at the LINE-1 and satellite 2 repetitive ele-
ments was mainly observed when chronic hepatitis and
liver cirrhosis progressed to HCC [100], and methylation
of CHFR and SYK, potential tumor-suppressor genes, in-
creased in advanced HCC [101, 102]. These findings sug-
gest that accumulation of aberrant DNA methylation in
non-cancerous tissues, or an epigenetic field for canceriza-
tion that is predisposed to cancer development, may also
be present in HCC, similar to that described above for H.
pylori infection in gastric cancer.
Importantly, the DNA methylation profile of liver cir-
rhosis and HCC is dependent on the type of hepatitis
virus. Nishida et al. [103] showed that methylated loci
were categorized into three groups: i) loci methylated in
normal tissues and that showed increased methylation
during HCC development; ii) loci methylated in non-
cancerous and HCC tissues; and iii) loci methylated more
densely and frequently in HCV+ HCC than in HBV+ and
virus-negative HCC. Other analyses of genome-wide DNA
methylation data also showed etiology-dependent methy-
lation profiles of cirrhosis and primary HCC [104, 105].
Mechanisms of induction of aberrant DNA methylation by
HBV and HCV
Aberrant DNA methylation may be induced by direct
action of a virus and also indirectly via chronicinflammation due to viral infection (Fig. 3). A direct
action is known for an HBV protein, hepatitis B virus
protein X (HBx). HBx was found to induce DNMT up-
regulation, leading to DNA methylation of the genes
involved in the Ras pathway and angiogenesis [106],
and to interact directly with DNMT3A to recruit it to
the promoters of IL-4R, a gene encoding a cytokine
receptor involved in apoptosis, and MT1F, a potential
tumor-suppressor gene, leading to their methylation-
silencing [107].
Chronic inflammation is also involved in the induction
of aberrant DNA methylation and thus in the produc-
tion of an epigenetic field for cancerization, similar to
the gastric carcinogenesis associated with H. pylori infec-
tion (Fig. 3). Okamoto et al. [26] analyzed genome-wide
DNA methylation in the livers of immunodeficient mice
Table 2 Applications for clinical cancer management
Application Example
Cancer diagnosis
Cancer risk Prediction of metachronous gastric cancer [22]
Cancer detection Early detection of cervical cancer [109]
Cancer prevention Suppression of H. pylori-induced gastric cancers
by 5-aza-2′-deoxycytidine in animal model [151]
Cancer therapy DNA demethylating agents and histone
deacetylase inhibitors (not specific to
infection-associated cancers) [155]
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In both systems, aberrant DNA methylation was in-
duced, and the induction was associated with increased
expression of an inflammation-related gene, Ifng, pro-
duced by NK cells, and reactive oxygen species (ROS)
production. When NK cell activity was suppressed by
the anti-asialo-GM-1 antibody, the induction of aberrant
DNA methylation was suppressed, demonstrating that
the NK-cell-dependent innate immune response was im-
portant for methylation induction [26].
Human papillomaviruses and squamous cell
carcinomas
Human papillomavirus (HPV) is related to the develop-
ment of HNSCC and cervical cancers [108]. Although
details of a mechanistic link between HPV and aberrant
DNA methylation are still very limited, clinical applica-
tion of aberrant DNA methylation in detection of cer-
vical cancers is now actively being investigated [109].
HPV is a circular, double-stranded DNA virus, and
more than 100 unique HPV types are known [110].
Among them, HPV types 16, 18, 31, 33, 35 and 45 are
high-risk HPV (hrHPV) [108]; 12.5–25 % of HNSCCs
are associated with infection by hrHPV types 16, 33, or
35, and HNSCCs in the oropharynx are particularly
strongly associated [110, 111]. Approximately 54 % and
17 % of invasive cervical cancer cases are associated with
hrHPV types 16 and 18, respectively [112].
Promoter hypermethylation is considered to be a
mechanism of HNSCC progression, although analysis
has been limited to a small number of tumor-suppressor
genes, such as p16, CDH1, RARβ, MGMT, DAPK, DCC,
GALR1, and GALR2 [113–115]. Methylation was more
frequently observed in HPV+ cells than in HPV- cells,
and DNMT3A expression was also higher in HPV+ cell
lines [116–118]. Methylation levels of LINE-1 repetitive
elements were higher in HPV+ HNSCC than in HPV-
cancer cells [119]. This finding was interesting, consider-
ing that most cancer cells are characterized by global hy-
pomethylation, including LINE-1 repetitive elements
[100]. The authors [100] suggested that HPV-infected
cells attempted to silence the virus by DNA methylation,
which might have resulted in increased methylation of
LINE-1 repetitive elements [119].
In cervical cancer, increased DNA methylation of
tumor-suppressor genes, such as p16, FHIT, GSTP1,
MAL and TSLC1, was observed [120–123]. Some of
these genes, such as CADM1 and MAL, were also meth-
ylated in cervical intraepithelial neoplasia (CIN), a pre-
cancerous lesion associated with hrHPV infections [124,
125], providing the presence of an accumulation of aber-
rant DNA methylation in non-cancerous tissues, or an
epigenetic field for cancerization, which is predisposed
to cancer development.Implications for cancer prevention, diagnosis and
therapy
A common characteristic of infection-associated cancers
is the presence of an epigenetic field for cancerization
[18–20]. In addition to infection-associated cancers, can-
cers associated with inflammation due to causes other
than infection (inflammation-associated cancer), such as
Barrett’s cancer of the esophagus, are also associated
with an epigenetic field [126]. Furthermore, prostate and
breast cancers, both of which are associated with hor-
monal signals [21], are also associated with an epigenetic
field [127, 128]. In addition, DNA methylation in non-
cancerous tissues has been associated with tumor ag-
gressiveness and worse patient outcome [129]. These
findings indicate that opportunities for cancer preven-
tion, diagnosis, and therapy are potentially widely applic-
able. In particular, cancer risk diagnosis is now reaching
a level of clinical use. Examples of such applications for
clinical management of infection-associated cancers are
summarized in Table 2.
Diagnosis of cancer risk
The extent of aberrant DNA methylation accumulation
in non-cancerous tissues, or the ‘severity’ of an epigen-
etic field, correlates with the risk of cancer development,
at least in some cancers, including gastric cancer. A re-
cent multicenter prospective cohort study convincingly
demonstrated the clinical utility of this concept [22]. In
the study, a gastric mucosal biopsy sample was obtained
from 826 patients who had undergone endoscopic resec-
tion of a gastric cancer, and DNA methylation levels of
three preselected marker genes, EMX1, NKX6-1, and
miR-124a-3 [47, 130], were measured. After a median
follow-up of 2.97 years, the patients with a high
methylation level of miR-124a-3 were shown to de-
velop metachronous gastric cancers with a statisti-
cally higher incidence (hazard ratio = 2.3, p = 0.042).
In addition, several promising DNA methylation
markers have been identified through retrospective
cohort studies [131–133].
Epigenetic cancer risk diagnosis is expected to achieve
cancer risk prediction that is very difficult by other
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ation is considered to reflect a patient’s life history, in-
cluding exposure to environmental carcinogenic factors
and how strongly the sampled tissue responded to the
carcinogens. Also, DNA methylation levels can be mea-
sured precisely and therefore have a methodological
advantage. The use of the extent or ‘severity’ of the epi-
genetic field as a cancer risk marker is expected to be
applicable to various types of cancers.Early detection of cancers
In HPV-associated cervical cancers, DNA methylation
markers have been found to be useful for triage of
hrHPV-positive women as a tool for screening [134].
Several methylation biomarkers were able to distinguish
cervical samples with intraepithelial neoplasia grade 2 or
3 (CIN2 or 3) from those with CIN1 or without any
intraepithelial lesions or malignancy [135–137]. A recent
prospective randomized clinical trial by Verhoef et al.
[109] compared methylation of preselected marker genes
MAL and miR-124-2 with cytology using self-collected
cervicovaginal specimens and showed that methylation
triage was at least as sensitive as cytology triage for de-
tection of CIN2 or worse. This large-scale randomized
prospective study clearly demonstrates the power of epi-
genetic analysis in detecting cervical cancer.
In EBV-associated NPC, Hutajulu et al. [138] detected
aberrant methylation of four tumor-suppressor genes
(DAPK1, DLC1, CDH13, and CADM1) in DNA from
nasopharyngeal brushing samples of cancer patients,
high-risk subjects, and healthy EBV carriers, and also de-
tected DNA methylation of CDH1, DAPK1, and p16 in
the peripheral blood of NPC patients. These reports in-
dicated that the DNA methylation of these genes might
be a useful serological marker for screening of primary
and local or regional recurrent NPC [139].Targets for cancer prevention
Suppression of accumulation of aberrant DNA methyla-
tion or elimination of accumulated methylation is ex-
pected to lead to a decreased cancer incidence. This
concept has been supported by evidence in genetically
engineered animal models for colon tumors [140–142],
lung tumors [143], blood cancers [144, 145], and squa-
mous cell carcinomas in the tongue and the esophagus
[146]. The mechanism has been explained by the induc-
tion of cellular differentiation and impairment of stem
cell function by decreased methylation due to reduced
expression of Dnmt1 [141, 145]. Also, administration of
a DNA demethylating agent, such as 5-aza-2′-deoxycyti-
dine, suppressed tumorigenesis in animal models for in-
testinal tumors [147], prostate cancer [148, 149], and
breast cancer [150].The plausibility of this strategy in infection-associated
cancers is of broad interest considering the large popula-
tion affected by these types of cancers. Niwa et al. [151]
showed that administration of 5-aza-2′-deoxycytidine
could suppress the development of H. pylori-induced
gastric cancers in Mongolian gerbils. In humans, because
epidemiological studies have shown an inverse associ-
ation between the use of nonsteroidal anti-inflammatory
drugs (NSAIDs) and incidence of colorectal cancer
disease-related death, NSAIDs are used to prevent colo-
rectal cancers [152]. Multiple mechanisms have been
proposed to explain the inverse association, including
enhancement of apoptosis of colonic epithelia [153,
154]. Therefore, it seems possible that suppression of in-
duction of epigenetic alterations might be effective in
infection-associated cancers.
Targets for cancer therapy
Regarding cancer therapy, epigenetic drugs have been
developed that target DNA methyltransferases and his-
tone modification regulators (deacetylases, methyltrans-
ferases, demethylases, and readers). DNA demethylating
agents and histone deacetylase inhibitors have already
been approved for hematological malignancies [155,
156]. Clinical trials for a broader range of tumors, in-
cluding solid tumors, are being extensively conducted,
and various combinations of different epigenetic drugs,
or an epigenetic drug and an anti-cancer drug, are also
being attempted. Although the targets of epigenetic drugs
do not appear to be specific to infection-associated can-
cers compared with other cancers, infection-associated
cancers may have more targets because infection is a po-
tent inducer of epigenetic alterations, and some of these
cancers might be a good subpopulation for epigenetic
therapy.
Conclusions and future directions
The induction of aberrant DNA methylation now ap-
pears to be the major mechanism by which viral and
bacterial infections in various tissues can induce cancer.
Therefore, the remaining crucial question is the molecu-
lar mechanism by which viral and bacterial infections in-
duce epigenetic alterations. It is clear that, for multiple
types of infections, aberrant DNA methylation is in-
duced via chronic inflammation, but the molecular
mechanisms by which chronic inflammation induces ab-
errant DNA methylation are mostly still unclear. At the
same time, some pathogens, such as EBV and HBV, dir-
ectly interfere with epigenetic regulators. Clarification of
these molecular mechanisms will have great value in
identifying novel targets for cancer prevention.
An epigenetic field for cancerization is a common char-
acteristic of infection-associated cancers. In addition, can-
cers associated with chronic inflammation due to causes
Hattori and Ushijima Genome Medicine  (2016) 8:10 Page 9 of 13other than infection also have an epigenetic field [126], be-
cause chronic inflammation is a potent inducer of aber-
rant DNA methylation. Furthermore, the presence of an
epigenetic field has been reported for hormone-associated
cancers [21]. The direct action of hormones on epigenetic
machinery has been suggested [157], and more research in
this area is also important.
Epigenetic field cancerization provides a broad range
of opportunities for cancer diagnosis, prevention, and
therapy. The ‘severity’ of an epigenetic field for canceri-
zation is promising as a cancer risk marker, as evidenced
by the multicenter prospective cohort study for meta-
chronous gastric cancer [22]. Epigenetic cancer risk
markers are considered to reflect the life history of indi-
viduals and thus can be effective because environmental
exposure is a major cause of human cancers [158]. To
bring the markers identified in retrospective cohort
studies into practice, more prospective studies in settings
with high clinical value are necessary. Early detection of
cancer is also a promising application of epigenetic
markers, and comparison of sensitivity and specificity
with markers now used in clinical practice is necessary.
The use of an epigenetic field as a target of cancer pre-
vention is also awaited. Given that the usefulness of sup-
pression of aberrant DNA methylation has been shown
for various types of tumors in animal models, develop-
ment of a method with minimal adverse effects appears
essential. However, current DNA demethylating agents
decitabine and azacytidine are mutagenic [159] and can-
not be used for cancer prevention. Meanwhile, suppres-
sion of chronic inflammation is expected to have
preventative value through multiple mechanisms [153,
154]. Drug repositioning, which uses drugs already
shown to be safe, may also become a useful strategy to
identify drugs targeting aberrant DNA methylation or an
epigenetic field, leading to inhibition of infection-
associated carcinogenesis.
Epigenetic therapy is currently approved only for
hematological malignancies, and as mentioned earlier its
application to solid tumors is actively being investigated
[160]. Because epigenetic alterations are induced by in-
fection and the resultant chronic inflammation, it is pos-
sible that at least some infection-associated cancers will
show a good response to epigenetic therapy. If so, identi-
fication of epigenomic signatures in tumors that will re-
spond appears to be a topic worthy of investigation.
Aberrant histone modifications have received relatively
limited attention, although they appear to occur more
often and much earlier than aberrant DNA methylation
in a mouse colitis model [27]. One major reason why
only a limited number of studies are available is the
technical difficulty of quantifying histone modifications,
especially for diagnostic applications. Development of a
method for precise measurement of histone modificationswould advance the field. From preventative and thera-
peutic viewpoints, many inhibitors of histone modification
enzymes and readers are currently being developed [155],
and aberrant histone modification induced by infection
may be a promising target.
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